Finance

Lists
Why is WST down 3,99%?
Dive Deeper
WST:NYSE
West Pharmaceutical Services Inc
392,48 $
-3,99%
(-16,30) 1D
385,33 $
-1,82% (-7,15)
After hours
Closed: 5 նոյ, 16:00:04 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for WST...
Open
408,54 $
High
409,81 $
Low
392,12 $
Mkt. cap
27,34 մլրդ
Avg. vol.
671,98 հզր
Volume
0,00
Dividend
0,26%
Quarterly dividend
0,26 $
Ex-dividend date
29 հլս, 2026 թ.
P/E ratio
44,02
52-wk high
438,27 $
52-wk low
223,83 $
EPS
8,92 $
Beta
1,13
Shares outstanding
69,66 մլն
No. of employees
11 հզր
Open
408,54 $
High
409,81 $
Low
392,12 $
Mkt. cap
27,34 մլրդ
Avg. vol.
671,98 հզր
Volume
0,00
Dividend
0,26%
Quarterly dividend
0,26 $
Ex-dividend date
29 հլս, 2026 թ.
P/E ratio
44,02
52-wk high
438,27 $
52-wk low
223,83 $
EPS
8,92 $
Beta
1,13
Shares outstanding
69,66 մլն
No. of employees
11 հզր
News stories
From web sources and news partners
Profile
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. Founded in 1923 by Herman O. West and J.R. Wike of Philadelphia, the company is headquartered in Exton, Pennsylvania. In its early years of development, West produced rubber components for packaging injectable drugs, providing a sterile environment for the producers of penicillin and insulin. Wikipedia
About West Pharmaceutical Services Inc
CEOEric M. Green
Employees10,8 հզր
Founded1923
HeadquartersWest Whiteland Township, Փենսիլվանիա, Միացյալ Նահանգներ
SectorHealth Care
Industry-
Analyst ratings
Based on 6 analysts giving stock ratings to WST in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for WST in the last 3 months.
Highest
Current 392,48 $
500,00 $ (+27,40%)
Average
478,17 $ (+21,83%)
Lowest
400,00 $ (+1,92%)
Analyst
Recommendation
Action
Price target
Projected
Date
Brendan Smith
TD Cowen
Buy
Maintained
500,00 $
+27,4%
10/29/2026
Daniel Markowitz CFA
Evercore ISI
Buy
Maintained
480,00 $
+22,3%
10/30/2026
Unknown Analyst
UBS
Buy
Maintained
495,00 $
+26,1%
10/30/2026
Joanne Wuensch
Citi
Buy
Reiterated
494,00 $
+25,9%
10/30/2026
Luke Sergott
Barclays
Buy
Maintained
500,00 $
+27,4%
10/30/2026
Kallum Titchmarsh
Morgan Stanley
Buy
Upgraded
400,00 $
+1,9%
09/22/2026
Doug Schenkel
UBS
Buy
Maintained
415,00 $
+5,7%
09/09/2026
Michael Ryskin
Bank of America Securities
Buy
Reiterated
410,00 $
+4,5%
07/24/2026
Matt Larew
William Blair
Buy
Maintained
-
-
07/23/2026
Curtis Moiles
Exane BNP Paribas
Buy
Initiated
447,00 $
+13,9%
07/13/2026
Paul Knight
KeyBanc
Buy
Maintained
390,00 $
-0,6%
07/02/2026
Michael Polark
Wolfe Research
Buy
Reiterated
375,00 $
-4,5%
06/01/2026
Patrick B Donnelly
Citi
Buy
Maintained
400,00 $
+1,9%
04/24/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
-
-
04/23/2026
Dan Leonard
UBS
Buy
Maintained
340,00 $
-13,4%
02/13/2026
Justin Bowers
Deutsche Bank
Buy
Maintained
315,00 $
-19,7%
02/13/2026
David Windley
Jefferies
Buy
Maintained
295,00 $
-24,8%
02/10/2026
Nico Chen
DBS
Buy
Maintained
320,00 $
-18,5%
01/28/2026
Last report
29 հոկ, 2026 թ.
Fiscal period
Q3 2026
2,66 $ / 2,20 $
+21,12%beat
Revenue / Est. (USD)
874,50 մլն / 826,55 մլն
+5,80%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
805,00 մլն
844,90 մլն
872,30 մլն
874,50 մլն
Cost of goods sold
501,10 մլն
548,50 մլն
543,10 մլն
527,10 մլն
Cost of revenue
501,10 մլն
548,50 մլն
543,10 մլն
527,10 մլն
Research and development expenses
21,80 մլն
15,80 մլն
19,70 մլն
18,30 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
107,50 մլն
99,50 մլն
112,00 մլն
108,80 մլն
Operating expense
129,70 մլն
113,10 մլն
133,20 մլն
125,50 մլն
Total operating expenses
630,80 մլն
661,60 մլն
676,30 մլն
652,60 մլն
Operating income
174,20 մլն
183,30 մլն
196,00 մլն
221,90 մլն
Other non operating income
600,00 հզր
-200,00 հզր
-200,00 հզր
-200,00 հզր
EBT including unusual items
165,40 մլն
183,50 մլն
186,20 մլն
272,00 մլն
EBT excluding unusual items
181,20 մլն
188,60 մլն
201,20 մլն
225,60 մլն
Income tax expense
33,30 մլն
44,70 մլն
32,20 մլն
58,00 մլն
Effective tax rate
20,13%
24,36%
17,29%
21,32%
Other operating expenses
400,00 հզր
-2,20 մլն
1,50 մլն
-1,60 մլն
Net income
132,10 մլն
138,80 մլն
154,00 մլն
214,00 մլն
Net profit margin
16,41%
16,43%
17,65%
24,47%
Earnings per share
2,04
2,13
2,37
2,66
Interest and investment income
5,30 մլն
5,10 մլն
3,80 մլն
4,30 մլն
Interest expense
-
-1,90 մլն
-2,60 մլն
-3,80 մլն
Net interest expenses
5,30 մլն
3,20 մլն
1,20 մլն
500,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
221,20 մլն
228,50 մլն
242,20 մլն
267,80 մլն
Gain or loss from assets sale
-
-
-
-55,70 մլն
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google Apps